

NEW THIS YEAR: CALL FOR POSTER ABSTRACTS *Due by Friday, March 2, 2012*

DIA/FDA Oligonucleotide-based Therapeutics 2012: Leveraging Regulatory and Industry Knowledge for Future Advancements

April 16-18, 2012

Washington Marriott Metro Center, Washington, DC



Antisense Pharma presents data on clinical studies

with trabedersen:

Oral Presentation

Title:

Trabedersen is Highly Effective Against TGF-beta 2 and Shows High Efficacy and Tolerability in Several Cancer Indications

Session ID:

Session 3C, Oncology

Presented by:

Dr. Hubert Heinrichs

Date:

April 16, 2012

Time:

1:30 to 2:00 pm

Location:

Washington Marriott Metro Center, Clinical Track, Washington, USA